Additional file 2 of Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma

Additional file 2. Tables S1–S14. Table S1. Differentially regulated genes in sensitive versus resistant NKTCL cell lines. Table S2. Differentially regulated pathways in sensitive versus resistant NKTCL cell lines. Table S3. Clinicopathological features of the patient cohort with NKTCL. Table S4. Differentially regulated pathways in TLE1-low and TLE1-high NKTCL tumor samples. Table S5. Differentially regulated pathways in NK-S1 cell line following BCV treatment. Table S6. Differentially regulated pathways in KAI-3 cell line following BCV treatment. Table S7. Differentially regulated pathways from scRNAseq clusters in KAI-3 and NK-S1 cell-lines following BCV treatment. Table S8. Differentially regulated pathways in PTCL-S1 cell line following BCV treatment. Table S9. NanoString pathway scores in EL4-C57BL/6 treatment groups. Table S10. NanoString cell-type scores in EL4-C57BL/6 treatment groups. Table S11. Differentially regulated genes in sensitive versus resistant B-cell lymphoma cell lines. Table S12. Multivariate analysis of TLE1 gene expression with overall survival in DLBCL datasets. Table S13. List of cell-line models used in the study. Table S14. List of antibodies and primers used in the study.